Mentioning Key Vendors Chiesi Farmaceutici SpA, Eli Lilly and Company, F. Hoffmann-La Roche Ltd
Pulmonary Arterial Hypertension - Pipeline Review, H1 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.
Request a sample report @ https://www.htfmarketreport.com/sample-report/280871-pulmonary-arterial-hypertension-pipeline-review
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus.
The Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 9, 11, 36, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
Access this report @ www.htfmarketreport.com/buy-now?fo…amp;report=280871
Reasons to access
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquire for Discount @ https://www.htfmarketreport.com/request-discount/280871-pulmonary-arterial-hypertension-pipeline-review
Table of Contents
List of Tables 5
List of Figures 7
Global Markets Direct Report Coverage 8
Pulmonary Arterial Hypertension - Overview 9
Pulmonary Arterial Hypertension - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Pulmonary Arterial Hypertension - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 31
Actelion Ltd 31
APT Therapeutics Inc 31
Arena Pharmaceuticals Inc 32
Ascendis Pharma A/S 32
Asklepion Pharmaceuticals LLC 33
AVEO Pharmaceuticals Inc 33
Bial - Portela & Ca SA 34
Camurus AB 34
Celsion Corp 35
Celtaxsys Inc 35
Chiesi Farmaceutici SpA 36
Eli Lilly and Company 36
F. Hoffmann-La Roche Ltd 37
Galectin Therapeutics Inc 37
HitGen LTD 38
Insmed Inc 38
INSYS Therapeutics Inc 39
INVENT Pharmaceuticals Inc 39
Johnson & Johnson 40
Kowa Company Ltd 40
Liquidia Technologies Inc 41
MannKind Corp 41
Mast Therapeutics Inc 42
Mezzion Pharma Co Ltd 42
miRagen Therapeutics Inc 43
Morphogen-IX Ltd 43
Nippon Kayaku Co Ltd 44
Nippon Shinyaku Co Ltd 44
Northern Therapeutics Inc 45
Novartis AG 45
Peloton Therapeutics Inc 46
PhaseBio Pharmaceuticals Inc 46
Pluristem Therapeutics Inc 47
Polyphor Ltd 47
Proteo Inc 48
Pulmokine Inc 48
Reata Pharmaceuticals Inc 49
Respira Therapeutics Inc 49
Reviva Pharmaceuticals Inc 50
Selten Pharma Inc 50
Serodus ASA 51
Silence Therapeutics Plc 51
SteadyMed Therapeutics Inc 52
Suda Ltd 52
Toray Industries Inc 53
United Therapeutics Corp 53
Vivus Inc 54
Pulmonary Arterial Hypertension - Drug Profiles 55
(macitentan + tadalafil) - Drug Profile 55
acebilustat - Drug Profile 56
Antibody to Inhibit TRAIL for Pulmonary Arterial Hypertension - Drug Profile 60
Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 61
APT-602 - Drug Profile 62
ascomycin - Drug Profile 63
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/280871-pulmonary-arterial-hypertension-pipeline-review
Category: Market Research Publishers and RetailersCompany about: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...
For more information: